# AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

> **NCT00180128** · PHASE4 · UNKNOWN · sponsor: **Technische Universität Dresden** · enrollment: 80 (estimated)

## Conditions studied

- Leukemia, Promyelocytic, Acute

## Interventions

- **DRUG:** all-trans retinoid acid
- **DRUG:** idarubicin
- **DRUG:** mitoxantrone
- **DRUG:** daunorubicin
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT00180128
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2011-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180128, "AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00180128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*